Your session is about to expire
← Back to Search
PEP-CMV Vaccine for Pediatric Brain Tumor
Study Summary
This trial will study whether the PEP-CMV vaccine can help treat high-grade glioma, diffuse intrinsic pontine glioma, and recurrent medulloblastoma in children.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can octogenarians participate in this research project?
"The ages of 3 to 25 are the only patients that will be considered for this trial. In total, there are 345 trials testing medications on children and 1346 studies involving seniors."
Why is PEP-CMV taken so often?
"PEP-CMV can be used to treat nitrosourea treatment, advance directives, and refractory, advanced mycosis fungoides."
In how many countries is this trial taking place?
"In total, there are 10 clinical trial sites currently enrolling patients. Some notable locations include Seattle Children's Hospital, Cincinnati Children's Hospital Medical Center, and Children's National Medical Center."
Does this experiment have any open slots for new participants?
"Unfortunately, this particular clinical trial is not presently looking for new patients. This study was initially posted on 11/15/2022 and last updated on 8/10/2022. There are 1631 other medical trials that are recruiting at this time though."
Do we have any previous data to compare these PEP-CMV results to?
"There are currently 218 ongoing trials studying PEP-CMV. 25 of these are Phase 3 clinical trials, which is the stage with the most human testing. The majority of these studies take place in Seoul and Songpa, but there are 4,820 total locations running PEP-CMV trials."
How many test subjects are needed for this experiment?
"This trial is not recruiting at this time, however, there are 1413 other clinical trials actively recruiting participants with diffuse intrinsic pontine glioma and 218 studies for PEP-CMV."
Which types of patients are best suited for this clinical trial?
"This trial is looking for 120 participants that have diffuse intrinsic pontine glioma and are between the ages of 3-25. Most importantly, patients must meet the following criteria: Karnofsky ≥ 50% for patients >16 years old or Lansky ≥ 50 for patients ≤ 16 years old. Additionally, even if a patient is unable to walk because of paralysis, as long as they can be wheeled around in a chair, they will be considered ambulatory for performance score assessment. For more information, please see Appendix I."
What sets this clinical trial apart from others?
"PEP-CMV has been researched since 2002 when the first clinical trial was conducted. Sixty people participated in this initial study that was sponsored by Schering-Plough. Based on the results of this 2002 study, PEP-CMV received Phase 2 drug approval. Currently, there are 218 live studies for PEP-CMV being conducted across 947 cities and 36 countries."
What are the government regulations on PEP-CMV?
"While there is some data supporting PEP-CMV's safety, it has not been proven effective yet and thus received a score of 2."
Share this study with friends
Copy Link
Messenger